Literature DB >> 4618458

In vitro susceptibility of Shigella strains to trimethoprim and sulfamethoxazole.

R C Rudoy, J D Nelson, K C Haltalin.   

Abstract

Trimethoprim and sulfamethoxazole were tested alone and in combination against 227 recently isolated Shigella strains. Variations in medium constituents and inoculum size were used to determine the optimal testing conditions. The plate dilution method with addition of 5% lysed horse blood to the susceptibility test medium and an inoculum size of 10(2) organisms was found to provide satisfactory results. All 227 strains were inhibited by low concentrations of trimethoprim, and all were susceptible to the combination of 0.06 mug of trimethoprim per ml and 1.25 mug of sulfamethoxazole per ml. Sixteen percent of these strains were resistant to ampicillin, 33% to tetracycline, 15% to chloramphenicol, and 27% to cephalothin. Based on these in vitro observations, trimethoprim and sulfamethoxazole appear worth evaluating for treatment of shigellosis due to multiply antibiotic-resistant strains.

Entities:  

Mesh:

Substances:

Year:  1974        PMID: 4618458      PMCID: PMC428990          DOI: 10.1128/AAC.5.5.439

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  13 in total

1.  IN VITRO SUSCEPTIBILITY OF SHIGELLAE TO SODIUM SULFADIAZINE AND TO EIGHT ANTIBIOTICS.

Authors:  K C HALTALIN; J D NELSON
Journal:  JAMA       Date:  1965-08-30       Impact factor: 56.272

Review 2.  Trimethoprim-sulfamethoxazole: in vitro microbiological aspects.

Authors:  S R Bushby
Journal:  J Infect Dis       Date:  1973-11       Impact factor: 5.226

3.  Resistance of shigellae to ampicillin and other antibiotics. Its clinical and epidemiological implications.

Authors:  S Ross; G Controni; W Khan
Journal:  JAMA       Date:  1972-07-03       Impact factor: 56.272

4.  Ampicillin and shigellosis.

Authors:  K C Haltalin
Journal:  Am J Dis Child       Date:  1973-03

5.  Practical aspects of testing sensitivity to trimethoprim and sulphonamide.

Authors:  P M Waterworth
Journal:  Postgrad Med J       Date:  1969-11       Impact factor: 2.401

6.  In-vitro sensitivity of Shigella sonnei to trimethoprim and sulphamethoxazole.

Authors:  K J Jarvis; G Scrimgeour
Journal:  J Med Microbiol       Date:  1970-08       Impact factor: 2.472

7.  Trimethoprim-sulphamethoxazole in enteric infections.

Authors:  C Franzén; G Lidin-Janson; B Nygren
Journal:  Scand J Infect Dis       Date:  1972

8.  Trimethoprim, a sulphonamide potentiator.

Authors:  S R Bushby; G H Hitchings
Journal:  Br J Pharmacol Chemother       Date:  1968-05

9.  Assay and pharmacokinetics of trimethoprim in man and animals.

Authors:  D E Schwartz; W H Ziegler
Journal:  Postgrad Med J       Date:  1969-11       Impact factor: 2.401

10.  Antibiotic susceptibility testing by a standardized single disk method.

Authors:  A W Bauer; W M Kirby; J C Sherris; M Turck
Journal:  Am J Clin Pathol       Date:  1966-04       Impact factor: 2.493

View more
  5 in total

1.  Pharmacokinetics and efficacy of trimethoprim-sulfamethoxazole in the treatment of gastroenteritis in children.

Authors:  M I Marks
Journal:  Can Med Assoc J       Date:  1975-06-14       Impact factor: 8.262

2.  Shigellosis in adults. Diagnostic difficulties and delays.

Authors:  J A Jacobson
Journal:  West J Med       Date:  1979-10

3.  Antimicrobial susceptibilities of shigellae isolated in Houston, Texas, in 1974.

Authors:  P A Byers; H L Dupont; M C Goldschmidt
Journal:  Antimicrob Agents Chemother       Date:  1976-02       Impact factor: 5.191

4.  Drug resistance and R plasmids in Salmonella typhi isolated in Korea.

Authors:  D Chun; S Y Seol; D T Cho; R Tak
Journal:  Antimicrob Agents Chemother       Date:  1977-02       Impact factor: 5.191

Review 5.  Co-trimoxazole (trimethoprim-sulfamethoxazole): an updated review of its antibacterial activity and clinical efficacy.

Authors:  G P Wormser; G T Keusch; R C Heel
Journal:  Drugs       Date:  1982-12       Impact factor: 9.546

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.